HSBC Holdings’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$70.6M Sell
119,235
-24,389
-17% -$12.1M 0.04% 416
2025
Q4
$70.1M Sell
143,624
-12,743
-8% -$5.93M 0.04% 411
2025
Q3
$65.6M Sell
156,367
-28,427
-15% -$9.56M 0.04% 422
2025
Q2
$53.1M Buy
184,794
+5,088
+3% +$1.52M 0.03% 467
2025
Q1
$55.4M Sell
179,706
-25,187
-12% -$8.63M 0.03% 458
2024
Q4
$72.4M Sell
204,893
-20,349
-9% -$7.48M 0.04% 392
2024
Q3
$80.7M Buy
225,242
+162,381
+258% +$54.9M 0.05% 370
2024
Q2
$20M Sell
62,861
-53,897
-46% -$14.3M 0.01% 679
2024
Q1
$26.8M Buy
116,758
+22,065
+23% +$4.98M 0.02% 619
2023
Q4
$20.8M Buy
94,693
+5,416
+6% +$1.25M 0.02% 658
2023
Q3
$20.2M Buy
89,277
+1,635
+2% +$377K 0.02% 625
2023
Q2
$19.4M Buy
87,642
+21,995
+34% +$4.87M 0.02% 633
2023
Q1
$14.7M Buy
65,647
+54,065
+467% +$13.3M 0.02% 706
2022
Q4
$3.2M Buy
11,582
+5,507
+91% +$1.39M ﹤0.01% 1484
2022
Q3
$1.27M Sell
6,075
-304
-5% -$68K ﹤0.01% 1729
2022
Q2
$1.51M Buy
6,379
+1,907
+43% +$388K ﹤0.01% 1722
2022
Q1
$801K Sell
4,472
-3,708
-45% -$706K ﹤0.01% 2099
2021
Q4
$1.77M Sell
8,180
-59,433
-88% -$11.7M ﹤0.01% 1750
2021
Q3
$12.6M Buy
67,613
+58,857
+672% +$11.6M 0.01% 794
2021
Q2
$1.57M Buy
+8,756
New +$1.67M ﹤0.01% 1537
2021
Q1
Sell
-7,713
Closed -$1.16M 3150
2020
Q4
$1.16M Sell
7,713
-1,842
-19% -$242K ﹤0.01% 1602
2020
Q3
$970K Sell
9,555
-438
-4% -$48.1K ﹤0.01% 1560
2020
Q2
$1.21M Sell
9,993
-3,957
-28% -$445K ﹤0.01% 1362
2020
Q1
$1.32M Sell
13,950
-5,467
-28% -$520K ﹤0.01% 1357
2019
Q4
$1.71M Sell
19,417
-2,491
-11% -$219K ﹤0.01% 1561
2019
Q3
$1.75M Sell
21,908
-66,644
-75% -$5.37M ﹤0.01% 1666
2019
Q2
$6.91M Buy
88,552
+31,432
+55% +$2.94M 0.01% 1010
2019
Q1
$6.7M Buy
57,120
+13,873
+32% +$1.62M 0.01% 1000
2018
Q4
$4.71M Sell
43,247
-4,316
-9% -$500K 0.01% 1129
2018
Q3
$6.08M Sell
47,563
-4,980
-9% -$616K 0.01% 1046
2018
Q2
$5.94M Sell
52,543
-4,379
-8% -$481K 0.01% 1040
2018
Q1
$6.4M Sell
56,922
-6,141
-10% -$780K 0.01% 1018
2017
Q4
$9.32M Buy
63,063
+9,904
+19% +$1.26M 0.01% 695
2017
Q3
$6.22M Sell
53,159
-20,825
-28% -$2.66M 0.01% 966
2017
Q2
$9.6M Buy
73,984
+7,303
+11% +$911K 0.02% 774
2017
Q1
$9.19M Buy
66,681
+418
+0.6% +$63.3K 0.02% 756
2016
Q4
$9.5M Sell
66,263
-7,017
-10% -$896K 0.02% 743
2016
Q3
$8.65M Sell
73,280
-32,141
-30% -$3.86M 0.02% 725
2016
Q2
$11.2M Buy
105,421
+34,040
+48% +$3.8M 0.03% 617
2016
Q1
$7.95M Buy
71,381
+35,734
+100% +$4.52M 0.02% 728
2015
Q4
$5.58M Sell
35,647
-8,913
-20% -$1.3M 0.01% 898
2015
Q3
$5.85M Buy
44,560
+15,429
+53% +$2.47M 0.01% 763
2015
Q2
$5.07M Buy
29,131
+16,786
+136% +$3.02M 0.01% 816
2015
Q1
$2.13M Sell
12,345
-24,791
-67% -$3.78M ﹤0.01% 1163
2014
Q4
$4.81M Sell
37,136
-1,486
-4% -$191K 0.01% 912
2014
Q3
$4.97M Sell
38,622
-57,676
-60% -$5.95M 0.01% 874
2014
Q2
$8.52M Buy
96,298
+4,990
+5% +$480K 0.02% 682
2014
Q1
$8.59M Buy
91,308
+31,790
+53% +$3.25M 0.02% 624
2013
Q4
$6.73M Sell
59,518
-68,768
-54% -$6.2M 0.02% 768
2013
Q3
$10.1M Sell
128,286
-47,746
-27% -$3.49M 0.03% 595
2013
Q2
$11.6M Buy
+176,032
New +$11.3M 0.03% 467

Other funds holding UTHR

HSBC Holdings's UTHR Position: Q1 2026 in Review

HSBC Holdings reduced its United Therapeutics (UTHR) stake by 17% in Q1 2026, selling an estimated $12.1M and leaving 119,235 shares worth $70.6M. The position accounts for 0.04% of the portfolio, ranked #416.

HSBC Holdings first reported a position in UTHR in Q2 2013 and has held it in 51 quarters since. The position peaked at $80.7M in Q3 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • HSBC Holdings held 119,235 shares of United Therapeutics worth $70.6M as of Q1 2026.
  • HSBC Holdings sold 24,389 United Therapeutics shares in Q1 2026, an estimated $12.1M.
  • United Therapeutics made up 0.04% of HSBC Holdings's portfolio in Q1 2026, its #416 holding.
  • HSBC Holdings first reported a position in United Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • HSBC Holdings's United Therapeutics position peaked at $80.7M in Q3 2024.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.